BcnPit Biennial Conference 26

Barcelona – Pittsburgh

XIV Conferència Biennal Barcelona Pittsburgh
del 13 al 15 de maig de 2026
Tot el dia
Emissió en línia
Hotel Porta Fira Com arribar
Aconsegueix el teu bitllet

Aquesta conferència s’ha convertit en una referència en el camp de la demència. Al maig de 2026, BcnPit tornarà a sorgir com un valuós fòrum on professionals de tot el món poden connectar-se i compartir el seu treball i perspectives sobre la demència.

Aquesta conferència d’alta qualitat reunirà panelistes de reconegut prestigi científic internacional i crearà un espai interactiu amb l’objectiu final d’ajudar a les persones afectades i a les seves famílies.

Ens veiem a Barcelona-Pittsburgh 2026!

PRESENCIAL BARCELONA-PITTSBURGH

Participa presencialment en aquesta trobada internacional exclusiva, connecta directament amb experts i viu una experiència única entre Barcelona i Pittsburgh.

BARCELONA-PITTSBURGH ONLINE

Segueix l’esdeveniment des d’on vulguis amb accés virtual. Gaudeix de ponències en directe, sessions interactives per avançar en el teu desenvolupament professional sense moure’t de casa.

Descobreix els ponents del BcnPit 2026

Professor of Neurology at the National and Kapodistrian University of Athens, with academic affiliation at Columbia University. His research focuses on cognitive reserve and lifestyle factors, including diet, in Alzheimer’s disease and aging.

Prof. Nikolaos Scarmeas, MD, PhD Professor of Neurology, National and Kapodistrian University of Athens

Clifford R. Jack Jr., M.D. is Professor of Radiology (Neuroradiology) and the Alexander Family Professor of Alzheimer’s Disease Research at Mayo Clinic in Rochester MN.

Prof. Clifford R. Jack, Jr., MD. Professor of Radiology and Alzheimer’s Disease Research, Mayo Clinic

Neuropsychologist specializing in neurodegenerative dementias and acquired brain injury.

Prof. James Becker Chief Executive Officer, Brite Wellness, Inc.

Distinguished Professor of Neurology and Neuroscience at the University of Yaoundé I, he is a leading figure in clinical and research leadership in Africa. Founder of the Brain Research Africa Initiative (BRAIN), his work focuses on neurodegeneration, epilepsy, and translational neuroscience. With over 230 publications, his contributions include advances in onchocerciasis-associated epilepsy and the development of the Actigraphic Sleep Score.

Alfred Njamnshi MD, MA, DMS, FMH Professor of Neurology and Neuroscience, FMBS, University of Yaoundé I, Cameroon

Dr. Wepnyu Yembe Njamnshi is a physician–scientist specializing in neuropsychology and brain health in Africa, and Director of Operations at Brain Research Africa Initiative (BRAIN). He leads major initiatives in dementia research, including the BUILD-FSA programme and the Cameroon National Dementia Plan Project. His work focuses on strengthening research capacity and advancing innovative solutions across the continent.

Yembe Njamnshi, MD, MSc Director of Operations, Brain Research Africa Initiative (BRAIN); Research Executive, Ministry of Public Health (Cameroon)

Associate Professor of Bioinformatics at the Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, within the Department of Biochemistry and Structural Biology at UT Health San Antonio, USA.
He also serves as Program Director of the African Initiative for Bioinformatics Online Training in Neurodegenerative Diseases (AI-BOND).

Bernard Fongang, PhD Bioinformatician and AI-BOND Program Director at UT Health San Antonio

His research focuses on the intersection of artificial intelligence and healthcare, developing advanced methods in biomedical machine vision, multimodal learning, and generalist AI to support clinical decision-making.
He is a Senior Member of IEEE and Fellow of the American Heart Association, with work funded by major institutions including NIH and Gates Ventures

Prof. Vijaya B. Kolachalama, PhD Vijaya B. Kolachalama, PhD, FAHA Associate Professor of Medicine and Computer Science, Boston University

Laia Montoliu-Gaya, PhD, Assistant Professor at University of Gothenburg

Laia Montoliu, PhD Assistant Professor at University of Gothenburg

Director of the Multiple Sclerosis Center of Catalonia (Cemcat) at Vall d’Hebron University Hospital and Head of the Neuroimmunology Research Group at the Vall d’Hebron Research Institute.

Xavier Montalbán, MD, PhD Director of the Multiple Sclerosis Center of Catalonia (Cemcat) and Head of Neuroimmunology Research, Vall d’Hebron

At Ace, he design CTs and other global CT from pharmaceutical companies, participate in international boards to improve CT management and promote research projects to validate novel biomarkers for an early detection of the disease and find novel therapeutical approaches.

Xavier Morató, PhD Pharmacy Unit at Ace

Bruno Vellas is a leading expert in geriatrics and healthy aging, founder of major international initiatives such as EADC, CTAD, and ICFSR.

Prof. Bruno Vellas, MD, PhD Professor of Medicine and President Founder of IHU HealthAge, Toulouse University Hospital

Prof. Michael T. Heneka is a neurologist and clinician-scientist with over 25 years of experience in neurodegenerative diseases. His research focuses on neuroinflammation and immune mechanisms in disorders such as Alzheimer’s and Parkinson’s disease.

Prof. Michael Heneka, MD, PhD Professor of Neurology and Neuroimmunology

He has more than 20 years of experience in basic, clinical and applied research in drug dependence, psychopathology and memory disorders.

Sergi Valero, PhD Head of Medical Psychology at Ace Alzheimer Center Barcelona

Dr. Villemagne is a physician–scientist and Tenured Professor specializing in the development of molecular biomarkers for the discovery, diagnosis, prognosis, and clinical trials of neurodegenerative diseases.

Prof. Victor L Villemagne, MD Tenured Professor and Co-Director of Molecular Biomarkers in Psychiatry at the University of Pittsburgh

Dr. Cano is in charge of the molecular biology unit of Ace Alzheimer Center Barcelona and her studies are related to the clinical evaluation of early biomarkers of Alzheimer’s disease.

Amanda Cano, PhD Postdoctoral Researcher at Ace

The main objective of his genomic research group is to understand the causes of Alzheimer’s disease and other dementias by integrating genetic, transcriptomic and proteomic data.

Agustín Ruiz, MD, PhD Director of Research at Ace Alzheimer Center Barcelona

Dr. Boada focuses her research on the treatment of AD and related dementias, especially on the genotype and phenotype of common degenerative diseases and the design of new pharmacological and non-pharmacological treatments.

Prof. Mercè Boada, MD, PhD Chief Medical Officer and founding member of Ace Alzheimer Center Barcelona

ZONA DE PONENTS

Per a facilitar la comunicació amb el personal del congrés, accedeix a l’àrea de ponents i troba tota la informació que necessites.

PROGRAMA DEL BCNPIT 2026

11:30 – 11:45
11:30 – 11:45
Introduced by Ace Alzheimer Center Barcelona
OPENING SESSION​
11:45 – 12:45
PANEL
BREAKING NEWS IN AD​
11:45
Next Challenges in Blood Biomarkers for Alzheimer’s Disease
12:05
Dementia Care in the Era of Neurotechnology
12:25
AI-based differential diagnosis of various dementias
12:45 – 13:15
PANEL
FRAGILITY
12:45
Clinical approach for healthy longevity and brain health
13:15 – 14:00
Lunch Break
14:00 – 15:00
PANEL
EPIDEMIOLOGY​
14:00
Developing sustainable research capacity for dementia in Africa: a BUILD-FSA and AI-BOND Perspective
14:15
Brain Research Africa Initiative (BRAIN): BRAIN’s approach to building
14:30
Learnings from the MS world
15:00 - 16:00
PANEL
STRUCTURAL MRI
15:00
Is the ATN framework one size fits all?
15:15
MRI in monitoring Alzheimer’s patients in the era of novel therapeutics
15:30
The role of structural MRI in dementia diagnosis
16:00 – 16:30
Coffee Break
16:30 – 17:30
PANEL
IA
16:30
Real world evidence generation from large medical databases
16:45
From words to biomarkers: leveraging AI and spontaneous speech in the Alzheimer's disease spectrum
17:00
Modeling Dementia via AI-enabled Patient Digital Twins
17:30 – 18:00
17:30 – 18:00
CEREMONY
LLUÍS TÁRRAGA AWARD CEREMONY
09:00 – 10:00
PANEL
BIOMARKERS
9:00
Blood-based biomarkers in the Alzheimer's continuum
9:15
Real-world experience for the identification of patients at risk of AD with plasma biomarkers
9:30
Connecting Alzheimer’s disease with Aging.
9:45
Plasma Aβ42/Aβ40 Identifies Early Amyloid Changes in PET Negative Individuals with Subjective Cognitive Decline
10:00 – 10:45
PANEL
PET
10:00
Implementation of the new NIA-AA diagnostic criteria for Alzheimer’s disease with PET
10:45 – 11:15
Coffee Break
11:15 – 12:15
PANEL
OMICS
11:15
High-Dimensional Proteomics for Neurodegeneration: From Blood Signatures to Mechanistic Insight in Alzheimer’s and Related Dementias
11:30
Beyond Plasma: Progranulin Reveals a Brain-Specific Neuroimmune Network
11:45
Epigenomic studies in Dementia
12:00
Using 'omics to identify synaptotherapeutic targets
12:15 – 12:30
12:15 – 12:30
CEREMONY
BOADA ROVIRA AWARD
12:30 – 13:00
PANEL
NEUROINFLAMMATION
12:30
Innate Immunity - a future treatment target in Alzheimer’s disease?
13:00 – 14:00
Lunch Break
14:00 – 15:00
PANEL
NEW DIAGNOSTIC ERA
14:00
Diagnostic Criteria and Absolute Risk of Impairment
14:20
The duality of diagnosis
15:00 – 16:30
PANEL
DISEASE-MODIFYING TREATMENTS
15:00
Latest results and next development steps for trontinemab in Alzheimer’s disease
15:30
Beyond clinical trials: early frontline experience with anti-amyloid therapies in Alzheimer’s disease
16:00
Evaluation and Treatment of Early Alzheimer’s Disease with Anti Amyloid Monoclonal Antibody in Neurology Community Clinics (USA)
16:30 – 17:00
Coffee Break
17:00 – 18:00
PANEL
NEW TREATMENT STRATEGIES
17:00
Valiltramiprosate Potentially First Oral Disease Modifying Treatment for Alzheimer’s Patients with APOE4/4 Genotype
17:15
Therapeutic plasma exchange with Albumin Replacement: Real-World Data from a single center study
17:30
Topline results of a Phase IV trial of EGb 761 in patients with Mild Cognitive Impairment (ACE-2020-EGb 761)
09:00 – 10:15
PANEL
NEW TREATMENT STRATEGIES
9:00
The Aβ disassembling compound PRI-002 does not cause ARIA in an ongoing phase 2 trial
9:15
Beyond the Lab: Real-World Implementation of Non Invasive Brain Stimulation in Cognitive Medicine
9:30
The Life's End Benefits of cannaBidiol and tetrahYdrocannabinol (LiBBY) Study
9:45
Sensory Neuromodulation for Alzheimer's Disease and Neuroprotection
10:15 – 10:45
PANEL
UPDATE ON VASCULAR DEMENTIA
10:30
Relationship between subclinical vascular disease and Alzheimer's disease pathology
10:45 – 11:15
Coffee Break
11:15 – 12:00
PANEL
NEUROPATHOLOGY
11:15
Neuropathological findings in patients treated with anti-amyloid therapy
11:30
Deep phenotyping of PSEN1 E280A brains: a multiomic approach
11:45
Alzheimer's Disease Pathology: Lessons from Longitudinal Epidemiologic Cohorts
12:00 – 13:00
PANEL
SOCIAL VALUE OF THE TREATMENT
12:30
Roundtable Discussion
12:30
Roundtable Discussion
13:00 – 13:30
13:00 – 13:30
Introduced by Ace Alzheimer Center Barcelona & University of Pittsburgh representatives
CLOSING SESSION

Patrocinadors del BCNPIT

Hotel Porta Fira
Plaça d'Europa, 45, 08908 L'Hospitalet de Llobregat, Barcelona Adreces a Google Maps

No perdis l’oportunitat de formar part d’una de les comunitats més grans en l’àmbit de la demència. Uneix-te a la propera XIV Biennal de Barcelona Pittsburgh 2026


BcnPit Registre